Due to the multiple links between tumor angiogenesis, tumor growth and Cox-2 expression, selective pharmacological inhibition of Cox-2 represents a promising therapeutic strategy for the treatment of malignant solid tumors. This evidence concerns the gene PTGS2 and neoplasm.